A single-arm, prospective, multicentre, open-label study to evaluate ofatumumab treatment effectiveness and patient-reported outcomes in patients with relapsing multiple sclerosis transitioning from dimethyl fumarate or fingolimod therapy

    Not Recruiting
Updated on 15 August 2022
disease or disorder
multiple sclerosis
relapsing multiple sclerosis
dimethyl fumarate


This study will look to see if ofatumumab works and is safe in adults with relapsing multiple sclerosis (MS) who are switching from their current oral medicines (dimethyl fumarate or fingolimod) because they no longer fully control their MS, and there have been disease activity-related events (relapses or MRI lesions).


A two-year study with about 550 participants.

Condition MS, Multiple Sclerosis, Dermatite Atopique modérée ou grave, Radiologically Isolated Syndrome
Clinical Study IdentifierTX264364
Last Modified on15 August 2022

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note